Fibrosis is an important wound-healing process in injured tissues, but excessive fibrosis is often observed in patients with chronic inflammation. Although oncostatin M (OSM) has been reported to play crucial roles for recovery from acute liver injury by inducing tissue inhibitor of metalloproteinase 1 (Timp1) expression, the role of OSM in chronic liver injury (CLI) is yet to be elucidated. Here, we show that OSM exerts powerful fibrogenic activity by regulating macrophage activation during CLI. Genetic ablation of the OSM gene alleviated fibrosis in a mouse model of chronic hepatitis. Conversely, continuous expression of OSM in a normal mouse liver by hydrodynamic tail vein injection (HTVi) induced severe fibrosis without necrotic damage of hepatocytes, indicating that OSM is involved in the fundamental process of liver fibrosis (LF) after hepatitis. In a primary coculture of hepatic stellate cells (HSCs) and hepatic macrophages (HMs), OSM up-regulated the expression of fibrogenic factors, such as transforming growth factor-b and platelet-derived growth factor in HMs, while inducing Timp1 expression in HSCs, suggesting the synergistic roles of OSM for collagen deposition in the liver. Fluorescence-activated cell sorting analyses using OSM-HTVi and OSM knockout mice have revealed that bone-marrow-derived monocyte/macrophage are responsive to OSM for profibrotic activation. Furthermore, depletion or blocking of HMs by administration of clodronate liposome or chemokine inhibitor prevented OSM-induced fibrosis. Conclusion: OSM plays a crucial role in LF by coordinating the phenotypic change of HMs and HSCs. Our data suggest that OSM is a promising therapeutic target for LF. (HEPATOLOGY 2018;67:296-312).
P atients with advanced liver fibrosis (LF) have poor prognosis because of impaired liver functions, adverse symptoms such as gastroesophageal varices and ascites, and hepatocellular carcinoma (HCC). (1, 2) In the injured liver, activated hepatic stellate cells (HSCs) are the main producer of extracellular matrix (ECM), including type1 collagen, whereas the ECM can be degraded by various proteinases such as matrix metalloproteinases (MMPs). The balance between ECM production and degradation is Abbreviations: ANOVA, analysis of variance; ALT, alanine transaminase; AST, aspartate transaminase; BMDM, bone-marrow-derived macrophage; CCL2, chemokine (C-C motif) ligand 2; CCR2, CC chemokine receptor 2; cDNA, complementary DNA; CLI, chronic liver injury; Clo-lipo, clodronate liposome; Cont-lipo, control liposome; DAMPs, damage-associated molecular patterns; ECM, extracellular matrix; FACS, fluorescence-activated cell sorting; GFAP, glial fibrillary acidic protein; HCC, hepatocellular carcinoma; H&E, hematoxylin-eosin; HM, hepatic macrophage; HSC, hepatic stellate cell; HTVi, hydrodynamic tail vein injection; IHC, immunohistochemistry; IL-6, interleukin-6; KC, Kupffer cell; KO, knockout; LF, liver fibrosis; LSEC, liver sinusoidal endothelial cell; MMP, matrix metalloproteinase; NPC, nonparenchymal cell; OSM, oncostatin M; Osmr, OSM receptor; PDGF, platelet-derived growth factor; PE, phycoerythrin; PSR, Picro-Sirius Red; TAA, thioacetamide; TGF-b, transforming growth factorb; Timp1, tissue inhibitor of metalloporoteinase 1; TNF-a, tumor necrosis factor-a; WT, wild type.
important for maintaining an appropriate amount of ECM in the liver. (3) When liver injury persists, however, activated HSCs and HSC-derived myofibroblasts continue to produce both collagens and tissue inhibitor of metalloproteinase 1 (Timp1), a suppressor of MMP-dependent degradation of collagens in the liver. Increased fibrogenesis and reduced fibrolysis results in excessive accumulation of ECM (i.e., pathological fibrosis). Activation of HSC is triggered and maintained by various factors in chronically injured liver. Among them, transforming growth factor-b (TGF-ß) and platelet-derived growth factor (PDGF) are the most well-known cytokines that activate and cause proliferation of HSCs, respectively. (4) (5) (6) Extensive studies on fibrosis have revealed the roles of these cytokines in fibrogenesis, and tremendous efforts have been made for treating fibrosis by targeting these cytokines. (7, 8) However, to date, there is no established therapy for fibrosis, partly because of the multifaceted roles of these cytokines depending on the cellular context. (9) Oncostatin M (OSM) is a member of interleukin-6 (IL-6) family cytokines with pleiotropic functions. OSM has several unique roles in anti-inflammation, metabolic function, regeneration, and hematopoiesis, (10) which are not shared by the other IL-6 family cytokines. Although the fibrotic function of OSM has been reported in lung and pancreas previously, (11) (12) (13) the mechanisms accounting for OSM-dependent fibrogenesis remain unclear. With regard to LF, it has been reported that OSM expression is elevated in both liver and serum of patients with cirrhosis or HCC, (14, 15) suggesting a correlation between OSM expression and fibrosis progression in the liver. It is well documented that OSM is involved in the expression of Timp1 in myofibroblasts and HSCs at the transcriptional level. (16, 17) We have reported previously that transiently up-regulated OSM after acute liver injury contributes to regeneration by inducing Timp1 to suppress excessive MMP activity. (18) These findings suggested that sustained expression of OSM could contribute to LF by Timp1-mediated suppression of fibrolysis during chronic liver injury (CLI). However, it is reported that overexpression of Timp1 alone is not sufficient to induce LF. (19) Therefore, it remains unknown whether OSM is essential to induce LF in vivo.
More recent studies have shed light on the fibrogenic roles of nonparenchymal cells (NPCs), such as liver sinusoidal endothelial cells (LSECs) and macrophages in addition to HSCs, demonstrating the cellular interaction among NPCs during fibrosis progression. (20) (21) (22) (23) However, the effect of OSM on NPCs during CLI remains largely unknown. Hepatic macrophages (HMs) are composed of at least two subpopulations: liver-resident Kupffer cells (KCs) and bonemarrow-derived macrophages (BMDMs). Although we have previously shown that OSM directly switches the phenotype of macrophages into anti-inflammatory M2-like in adipose tissue, (24) the role of OSM for HMs remained uninvestigated.
In this study, we show that OSM deficiency attenuated LF in the chronically injured liver. In addition, we establish a novel murine model of LF by expressing OSM continuously in the liver. Further analyses using an in vitro coculture system and in vivo inhibition of HMs demonstrated that the interaction between HSCs and HMs are essential for OSM-induced fibrogenesis in the liver. In particular, fluorescenceactivated cell sorting (FACS) analysis and the blocking of macrophage infiltration by chemokine inhibitor revealed that the profibrotic activation of BMDM by OSM contributes to LF. Taken together, these data indicate that OSM is a critical factor that contributes to LF by regulating the cooperation between HSCs and HMs.
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Materials and Methods

ANIMALS AND TREATMENT
In this study, we used 7-to 9-week-old mice. C57BL/6J mice were purchased from Clea Japan, Inc. (Tokyo, Japan). OSM knockout (KO) mice were generated as described. (25) All animals were maintained in a standard specific-pathogen free room at our animal facility. All mouse studies were conducted in accord with institutional procedures and approved by the Animal Care and Use committee of the Institute of Molecular and Cellular Biosciences, The University of Tokyo (approval nos. 2501, 2501-1, 2609, and 2706) and the National Center for Global Health and Medicine Research Institute (approval no. 16069). For a mouse model of LF, thioacetamide (TAA) was administered with drinking water (0.03% v/v) for 12 weeks.
DEPLETION AND INHIBITION OF HMs IN VIVO
To deplete hepatic macrophages, 20lL of clodronateliposome or control-liposome (Katayama Chemical Industries, Osaka, Japan) were intraperitoneally injected two times every 3 days after OSM-HTVi (hydrodynamic tail vein injection). For inhibition of infiltrating macrophage, CC chemokine receptor 2; CCR2 inhibitor RS102895 (Sigma-Aldrich, St. Louis, MO) was diluted in drinking water with a final concentration of 0.05 g/L. CCR2 or control water was given to mice ad libitum from 3 days after OSM-HTVi treatment, respectively.
HTVi
To overexpress OSM or Timp1 continuously in mouse livers, we used HTVi as described. (26) Briefly, this method delivers injected DNA to hepatocytes efficiently in liver through the vena cava and central vein by relatively high-pressure tail vein injection. In addition, the expression vector used in this experiment is pLIVE with the albumin promoter for expression of inserted complementary DNA (cDNA). The inserted cDNA is expressed efficiently in hepatocytes around the central vein under the control of the Albumin promoter by the HTVi method. We constructed pLIVE vector containing the mOSM cDNA (pLIVE-OSM) or Timp1 cDNA (pLIVE-Timp1). One microgram of pLIVE-OSM or 20 lg of pLIVE-Timp1 were diluted in 2 mL of TransIT-EE Hydrodynamic Delivery solution (Mirus Bio, Madison, WI) and injected into an 8-week-old mouse from the tail vein. pLIVE inserted with LacZ cDNA was used as the control vector.
ISOLATION OF HEPATOCYTES, HSCs, LSECs, AND HMs
A cell suspension of hepatocytes and NPCs was obtained from mouse liver by the modified collagenase perfusion method, as described. (26) HSCs were isolated as described. (27) Purity was >90% based on vitamin A content by ultraviolet excitation in flow cytometric analysis. For flow cytometric analysis and FACS of NPCs, CantoII (Becton, Dickinson and Company, Franklin Lakes, NJ) and Moflo XDP (Beckman-Coulter, Fullerton, CA) were used, respectively. LSECs were isolated from NPCs by FACS using an antimouse Stabillin-2 antibody as described. (26) For HM isolation, we skipped the step of Percoll centrifugation to prevent loss of the liver-resident macrophage population. For primary culture of HMs, samples were sorted from normal liver by an autoMACS Pro (Miltenyi Biotec, K.K., Tokyo, Japan) using a phycoerythrin (PE)-conjugated F4/80 antibody and anti-PE microbeads. The sorting was repeated to increase the purity of macrophages. For mRNA analysis, HMs were sorted by a combination of anti-F4/80, CD11b, Ly6G, and CD45 antibodies (BioLegend, San Diego, CA).
PRIMARY CULTURE OF HSCs, LSECs, AND HMs
HSCs, LSECs, and HMs were seeded in collagen type 1-coated six-well dishes (BD Bioscience) at 5 3 10 5 cells per well with Dulbecco's modified Eagle's medium (Sigma-Aldrich) containing 2% B-27 and antibiotics. In LSEC culture, vascular endothelial growth factor A was added at a final concentration of 10 ng/mL. After 12 hours, unattached cells were washed out and mOSM was added at a final concentration of 10 ng/mL. Total RNA was extracted from cultured cells 24 and 48 hours after OSM administration. For a coculture experiment, isolated LSECs or HMs from normal liver were cultured with or without OSM for 3 days and then each supernatant was collected, respectively. Independently, isolated HSCs were precultured for 12 hours, and then half of the HSC culture medium was exchanged with the supernatant of LSEC or HM culture described above. HSC was harvested for RNA extraction 2 days later.
HEMATOXYLIN-EOSIN, PICRO-SIRIUS RED STAINING, AND IMMUNOHISTOCHEMISTRY
Liver cryosections (8 lm) were mounted on glass slides and fixed at room temperature for 10 minutes with 4% paraformaldehyde for hematoxylin-eosin (H&E) staining and immunohistochemistry (IHC), and overnight with Bouin's solution (Sigma-Aldrich) for Picro-Sirius Red (PSR) staining. PSR staining was performed as described. (26) All images were captured using All-in-one BZX-700 (Keyence, Osaka, Japan). For IHC analysis, we used Rat monoclonal antimouse F4/80, CD11b, Ly6C (BioLegend), rabbit polyclonal antimouse collagen type 1 (Bio-Rad, Hercules, CA), and glial fibrillary acidic protein (GFAP; Abcam, Cambridge, CA) antibodies.
QUANTITATIVE ANALYSIS OF FIBROSIS AND MACROPHAGE
Accumulation of collagen fiber in liver was evaluated by PSR staining and hydroxyproline content. Hydoxyproline content was measured by high-performance liquid chromatography. (28, 29) Fibrotic regions were identified as PSR positive staining by detecting the red-colored area with Keyence BZ-analyzer. The number of immunostained cells was quantified by the Hybrid Cell Count function of the Keyence BZanalyzer. For unbiased quantitative analyses of broad fields of liver specimen, the joined area (19.6 mm 2 ) from 21 consecutive high-power images was analyzed.
STATISTICAL ANALYSIS
For comparison of two groups, a two-tailed unpaired t test was used in most experiments. In the case of four samples or less, the Mann-Whitney U test was applied. For comparison of three groups, one-way analysis of variance (ANOVA) was applied, and once F-test was significant, multiple comparisons between each group were conducted by Tukey' s multiple comparisons.
Results
LACK OF OSM ALLEVIATES FIBROSIS IN CLI
To evaluate the correlation between OSM and LF, we first examined the collagen deposition and fibrosisrelated gene expression in three murine models of LF by TAA administration, repeated injection of carbon tetrachloride, and bile duct ligation. Expression of type1 collagen, Timp1, and Osm was up-regulated along with the accumulation of collagens by PSR staining after liver injury in all tested models (Supporting Fig.  S1 ). To further investigate the role of OSM in LF, we chose the TAA model, because this model shows mild and prolonged elevation of serum hepatic injury marker alanine transaminase (ALT), which resembles the pathophysiology of patients with fibrosis. (30, 31) The increase of serum OSM level in TAAadministered mice was confirmed by enzyme-linked immunosorbent assay (Supporting Fig. S2 ). To identify the cell expressing OSM during LF, we prepared hepatocytes, CD45 1 blood cells, and CD45 -NPCs from injured liver 2 weeks after TAA administration. Gene expression analysis by qPCR showed that OSM was predominantly expressed in blood cells, but not in hepatocytes ( Fig. 1A ). Further subdivision of blood cells by FACS (Supporting Fig. S3 ) revealed that immune cells, especially neutrophil and BMDM, are the main source of OSM in TAA-injured liver ( Fig. 1A) .
To investigate whether OSM signaling is responsible for fibrogenesis in chronically injured liver, we next evaluated the level of LF using the OSM KO mouse. After 12 weeks of TAA administration, PSR staining revealed that the fibrotic area of the OSM KO mouse was significantly decreased compared to that of wildtype (WT) mouse ( Fig. 1B,C) . Consistent with this observation, the hydroxyproline content of the liver, which reflects the amount of collagen, was decreased significantly in OSM KO mice compared to WT mice (Fig. 1C ). The expression of fibrosis-related genes, Collagen1a1 and Timp1, were also significantly reduced in OSM KO mouse liver ( Fig. 1D ). During liver injury, hepatocytic damage seemed to be comparable between genotypes as judged by histochemical analysis and levels of serum hepatic injury markers, aspartate transaminase (AST) and ALT (Fig. 1E,F) . Therefore, it is unlikely that the difference of hepatic damage to TAA between genotypes accounts for this phenotype. These results suggested that continuous expression of OSM is involved in the progression of LF.
CONTINUOUS EXPRESSION OF OSM IS SUFFICIENT TO INDUCE LF
To investigate whether sustained expression of OSM in the liver is sufficient to induce LF, we used HTVi, which enables continuous expression of exogenous cDNA in the liver. After gene delivery of OSM cDNA by HTVi, OSM expression was maintained for at least 4 weeks ( Fig. 2A ). Because the used vector is controlled by the Albumin promoter, liver-specific expression was expected. In fact, successful expression of OSM in hepatocytes was confirmed by qPCR (Supporting Fig. S4A ). To our surprise, mice with HTViinduced OSM overexpression (OSM-HTVi) showed a considerable degree of LF even at 1 week postinjection ( Fig. 2B , upper panels). After 2 weeks postinjection, quantitative analysis of PSR staining in OSM-HTVi liver showed a significant increase in the fibrosis area compared to control mice (Fig. 2C) , indicating that OSM is a strong inducer of LF. Consistent with reports that Timp1 is a transcriptional target of OSM signaling, (16, 17) OSM-HTVi liver showed upregulation of Timp1, as expected (Fig. 2D) . Intriguingly, expression levels of Collagen1a1 mRNA were also elevated in OSM-HTVi mice (Fig. 2D) . These results suggested that continuous expression of OSM in the liver could induce not only Timp1, but also type1 collagen at gene expression level, thereby synergistically inducing the accumulation of collagens.
More surprisingly, no hepatic damage seemed to occur in OSM-HTVi liver. Although some kind of immune cells were observed within the fibrotic area ( Fig. 2B ), serum ALT levels were within the normal range during fibrosis progression ( Fig. 2E ). Propidium iodide staining in vivo showed no sign of apparent hepatocytic necrosis in OSM-HTVi mice, whereas several necrotic hepatocytes and serum ALT elevation were observed in the conventional TAA model ( Fig.  2E and Supporting Fig. S5A ). These data are reasonable because serum ALT is a deviation enzyme from necrotic hepatoyctes. The concentration of serum tumor necrosis factor-a (TNF-a) of OSM-HTVi mice was comparable to that of control-HTVi mice and lower than that of TAA-injured mice (Supporting Fig.  S5B ), supporting that OSM was not involved in cytotoxic inflammation in OSM-HTVi liver. To further elucidate the mechanism underlying OSM-dependent liver fibrosis, we examined the expression profile of OSM receptor (Osmr) mRNA in NPCs and hepatocytes. OSMR was highly expressed in NPC fraction, whereas it was hardly detected in hepatocytes in both OSM-HTVi and control-HTVi livers (Fig. 2F) . These results strongly suggested that LF in the OSM-HTVi mouse was caused by a direct effect of OSM on NPCs rather than a consequence of immune response following hepatic injury. Therefore, we focused on the effect of OSM on NPCs.
OSM PARTIALLY ACTIVATES HSCs
To identify the cell type responsible for OSMinduced fibrosis, we first examined the expression profile of Osmr mRNA in HSCs, LSECs, and F4/80 1 HMs (Fig. 3A) . As a result, all NPCs expressed OSMR. Then, we examined whether OSM is able to activate HSCs using freshly isolated HSCs from normal liver (Fig. 3B) , because activated HSCs are the main fibrogenic cells that express both Timp1 and type 1 collagen during fibrogenesis. In the presence of OSM, cultured HSCs exhibited apparent morphological change and marked up-regulation of Timp1 expression ( Fig. 3C,D) . At first, we expected that the morphological change of HSCs might be a sign of activation, because the activated HSC is known to transdifferentiate into a myofibroblast-like cell, producing an excess of collagens in the course of LF. Unexpectedly, however, expression of type 1 collagen was not promoted in HSCs in vitro following OSM stimulation (Fig. 3D) , whereas it was up-regulated in OSM-HTVi liver in vivo (Fig. 2D ). Considering that continuous expression of Timp1 by HTVi was not enough to induce LF (Fig. 3E,F) , up-regulation of type 1 collagen in the liver is crucial for OSM-induced fibrosis. This discrepancy between in vitro and in vivo experiments may be explained by the difference of the microenvironment surrounding HSCs, that is, the contribution of other OSM-responsive NPCs to HSC activation in vivo.
OSM INDIRECTLY ACTIVATES HSCs BY HM ACTIVATION
IHC analysis using cell-type-specific markers demonstrated the close proximity of Stabilin2-positive LSECs and GFAP-positive HSCs in livers of control, OSM-HTVi, and TAA-injured mice (Supporting Fig. S6A ). Because LSECs showed high expression of OSMR (Fig. 3A) , we first examined whether LSECs contributed to the up-regulation of type 1 collagen in HSCs by paracrine signaling. LSECs isolated from normal liver were cultured with or without OSM for 3 days, and then the supernatant was added into the primary culture of HSCs (Supporting Fig. S6B ). Although OSM induced morphological change of LSECs, we found no significant difference in collagen expression of HSCs irrespective of OSM stimulation (Supporting Fig. S6C,D ), suggesting that LSECs may not be involved in OSM-induced collagen expression in HSCs.
Next, we investigated the contribution of macrophages to OSM-induced fibrogenesis, because they are known to be responsible for fibrosis in various organs, including the liver, (20, 21) and HMs were also shown to express OSMR (Fig. 3A) . IHC using anti-F4/80 antibody, a macrophage marker, demonstrated accumulation of numerous macrophages within the fibrotic regions of both TAA-injured and OSM-HTVi livers (Fig. 4A) . To investigate the role of HMs in HSC activation, F4/80-positive HMs isolated from normal liver were cultured in the presence or absence of OSM for 3 days, and then each supernatant was added to the primary culture of HSCs (Fig. 4B ). Strikingly, we found that the supernatant from HMs stimulated by OSM promoted the expression of type 1 collagen in HSCs (Fig. 4C ). Furthermore, we isolated F4/80-positive HMs from OSM-HTVi or control-HTVi liver to evaluate the effect of each culture supernatant on HSC activation in vitro. As a result, the supernatant of OSM-HTVi-derived HMs culture significantly increased type 1 collagen expression in HSCs compared to that of control HMs (Fig. 4D) . These results strongly suggested that some secretory factors from OSM-stimulated macrophages are required for fibrogenic activation of HSCs. In fact, expression of TGF-ß1, the most well-known driver of tissue fibrosis, as well as PDGF-B, a proliferative factor for myofibroblasts, were up-regulated in HMs stimulated by OSM both in vitro and in vivo (Fig. 4E,F Fig. S7 ). These results strongly suggest that HMs acquire fibrogenic phenotype by OSM stimulus. Additionally, OSM-HTVi-derived HMs showed lower expression level of proinflammatory cytokines, such as IL-6, TNF-a, and IL-1ß than control-HTVi-derived HMs (Supporting Fig. S8 ).
and Supporting
HMs ARE ESSENTIAL FOR OSM-INDUCED LF
To investigate whether HMs are indispensable for OSM-induced fibrosis in vivo, we depleted HMs by injecting clodronate liposome (Clo-lipo) during fibrogensis (Fig. 5A ). Depletion of HMs in the liver was confirmed by qPCR and IHC (Fig. 5B,C) , and the Clo-lipo treatment resulted in remarkable decrease of collagen deposition in OSM-HTVi liver compared to the control liposome (Cont-lipo; Fig. 5C ,D and Supporting Fig. S9) . Notably, OSM-induced up-regulation of type 1 collagen was dampened in liver treated with Clo-lipo ( Fig. 5E ), indicating that HM is required for collagen production in OSM-HTVi liver. Concurrently, up-regulation of TGF-ß1 and PDGF-B in OSM-HTVi liver was suppressed by HM depletion ( Fig. 5E ), which is consistent with the result that OSM up-regulated these fibrogenic cytokines in HMs in vitro (Fig. 4E,F) . Taken together, these results indicate that HMs are the main cellular source of fibrogenic cytokines in this model and play a crucial role in OSM-induced fibrogensis by promoting collagen production in HSCs.
BMDMs ACCUMULATE IN THE FIBROTIC AREA OF OSM-HTVi LIVER
HMs are composed of at least two subpopulations: BMDMs and liver-resident KCs. Whereas the KC is a dominant macrophage population in normal liver, the BMDM is recruited from bone marrow to injured liver. It was reported that KCs and BMDMs can be subdivided by FACS based on the expression profiles of F4/80 and CD11b; KCs and BMDMs are identified as F4/80 hi CD11b intermediate and F4/80 intermediate CD11b hi , respectively (Supporting Fig. S3 ). (32) Therefore, we next tried to investigate which subpopulation of HM is critical for OSM-induced fibrosis. IHC, using anti-F4/80 antibody, demonstrated that there were many F4/80 1 macrophages within the fibrotic area around the central vein of the OSM-HTVi liver, whereas few macrophages were observed around the central vein of the control liver ( Fig. 6A and Supporting Fig. S10 ). However, it was impossible to identify whether these accumulating HMs are KCs or BMDMs, because both cells express F4/80. In contrast, IHC of serial sections with anti-CD11b antibody revealed that CD11b stained the accumulating cells within the fibrotic area in OSM-HTVi liver, but not F4/80-stained KCs of control liver, in our experimental settings ( Fig. 6B and Supporting Fig. S11 ). Similarly, accumulating cells in the fibrotic area were also positive for Ly6C, a marker for infiltrating monocyte/ macrophages (Supporting Fig. S12A ), strongly suggesting that these F4/80 1 macrophages are CD11b hi BMDMs. Consistently, FACS-based analysis showed that the ratio of BMDM relative to F4/80 1 HM was significantly increased in OSM-HTVi liver compared to control-HTVi liver (Supporting Fig. S12B ). Therefore, we hypothesized that activated BMDMs accumulating in fibrotic areas contribute critically to OSMinduced fibrosis. To address this possibility, we isolated BMDM and KC fractions from control-and OSM-HTVi livers by FACS to compare expression of TGF-ß1 (Fig. 6C ). Gene expression of TGF-ß1 in BMDMs and KCs derived from OSM-HTVi liver was higher than that from control-HTVi liver (Fig.  6C ). In addition, some M2 marker genes were upregulated in BMDMs or KCs isolated from OSM-HTVi liver (Supporting Fig. S13 ). To investigate whether OSM-induced profibrotic activation of HMs also occurs in the chronically injured liver, we isolated BMDMs and KCs from TAA-administered OSM KO and WT mice (Fig. 6D ). Gene expression of TGF-ß1 in BMDMs derived from OSM KO mice was lower than that from WT mice, whereas KCs showed comparable TGF-ß1 expression irrespective of genotypes (Fig. 6D) . Taken together, these results suggest that at least BMDMs are responsive to OSM stimulus, and that OSM contributes to fibrogenesis by switching the phenotype of BMDM to profibrotic one in chronically injured liver as well as OSM-HTVi liver.
BMDMs ARE RESPONSIBLE FOR OSM-INDUCED PROFIBROTIC EFFECT
In general, the BMDM is recruited from bone marrow by chemoattraction. Chemokine (CAC motif) ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, is a well-known chemokine related to monocyte/macrophage attraction. To investigate whether OSM is involved in the recruitment as well as profibrotic activation of the BMDM, we examined the gene expression of CCL2 between OSM-HTVi and control-HTVi livers. As a result, CCL2 was significantly up-regulated in OSM-HTVi liver compared to control liver (Fig. 7A ), suggesting that the BMDM is recruited from bone marrow by the CCL2/CCR2 signaling pathway in OSM-HTVi liver. To focus on the role of BMDMs in OSM-induced liver fibrogenesis, we tested a CCR2 inhibitor that is expected to selectively block the recruitment of only BMDMs, whereas Clo-lipo depleted both KCs and BMDMs (Fig. 7B) . Expectedly, administration of CCR2 inhibitor (RS102895) into the OSM-HTVi mouse almost completely blocked the infiltration of CD11b-stained BMDMs (Fig. 7C, upper panel) without affecting resident F4/80-stained KCs (Fig. 7C, lower panel) . Concomitantly, CCR2 inhibitor-treated mice alleviated LF ( Fig. 7D and E) , accompanied by decrease of type 1 collagen expression compared to vehicle-treated mice 
Discussion
In this study, we clearly showed the contribution of OSM to LF using the OSM KO mouse. We further established a novel LF model using HTVi-mediated OSM expression. This model is quite unique because of the following points: First, fibrosis progression is very rapid, and considerable ECM deposition is observed even after 1 week postinjection. Though some transgenic mouse models for LF have been reported by overexpressing fibrogenic cytokines, such as TGF-b1 and PDGFB, it takes several weeks or months to develop LF. (33, 34) Such rapid progression of fibrosis in our OSM-HTVi model supports the notion that OSM is a strong inducer of fibrosis. Second, this model showed no sign of hepatocellular necrosis during fibrosis progression. This characteristic is advantageous to investigate the fundamental process of fibrogenesis, because it does not induce multiple cytokines associated with inflammation. Third, this study demonstrates that continuous expression of OSM causes LF in vivo. Though OSM has been suggested to be fibrogenic in chronic hepatitis, most of the mechanistic studies were based on in vitro experiments. Therefore, this model enabled us to delineate the cellcell interaction relevant to LF induced by OSM in vivo.
Mechanistically, the induction of Timp1 expression by OSM has been well documented. (16, 18) Consistently, Timp1 expression was increased in OSM-HTVi liver, which might account for the progression of LF by suppressing MMP-dependent fibrolysis. However, overexpression of Timp1 in the normal liver by HTVi was not sufficient to induce LF by itself (Fig.  3E,F) . Therefore, it is likely that OSM-induced Timp1 expression in HSCs plays a supportive role by stabilizing deposited collagens.
On the other hand, the regulation of type 1 collagen expression in HSCs by OSM has not been reported, whereas one previous study reported that OSM increased collagen production posttranscriptionally without transcriptional regulation. (17) Consistently, we could not detect the up-regulation of type 1 collagen by OSM in the primary culture of HSCs. Instead, OSM-stimulated macrophage was shown to induce type 1 collagen in HSCs by both in vitro and in vivo experiments. Because depletion or inhibition of macrophage attenuates OSM-induced type 1 collagen expression in the liver, OSM not only directly stimulates HSC to express Timp1, but also indirectly induces type 1 collagen by macrophages. It is conceivable that both direct and indirect effect of OSM on HSCs is crucial for the promotion of LF by OSM.
Although it has been well known that macrophages play crucial roles for various pathogenesis, including fibrosis, (20, 35, 36) the nature of profibrotic macrophage during CLI is unclear. The broad spectrum of macrophage functions and phenotypes has been often classified either into "classically activated" proinflammatory macrophage (M1) or "alternatively activated" antiinflammatory/proreparative macrophage (M2). (36, 37) Whereas most of the previous studies classified macrophages in M1/M2 subtypes, a more recent study showed the presence of macrophage with mixed phenotypes of the M1/M2 classification in LF, suggesting that the conventional classification does not always account for the complex heterogeneity of hepatic macrophages in vivo. (32) Considering that infiltrating monocyte/macrophages can switch their phenotypes at the injury site, (38, 39) the diverse environmental factors, such as damage-associated molecular patterns (DAMPs), (40) (41) (42) chemokines, (43) and cytokines, (21) are assumed to affect the activation status of HMs. To better understand the process of liver fibrogenesis, it is important to identify key environmental factors responsible for profibrotic activation of HMs.
The present study demonstrated that OSM plays a possible role in LF by phenotypic change of BMDMs as well as their recruitment by the CCL2/CCR2 pathway. However, in the experiment using chemokine inhibitor, we cannot rule out the possibility that the CCR2 inhibitor may affect HSC directly. The chimeric mouse, of which bone marrow is substituted with CCR2-deficient bone marrow, may be useful to clarify the role of BMDMs in OSM-mediated LF.
Interestingly, the OSM-HTVi model showed no sign of hepatocellular necrosis, indicating that OSMinduced fibrosis does not require the release of DAMPs. In liver injury, DAMPs from necrotic cells recruit circulating monocyte/macrophages into the liver by chemoattraction and the infiltrating macrophages secrete proinflammatory cytokines, leading to further destruction of tissue. Therefore, OSM-induced profibrotic macrophages seem to be different from such proinflammatory macrophages. In fact, we and other groups have reported that OSM has an antiinflammatory role in some diseases. (24, (44) (45) (46) Consistently, the accumulating macrophages exhibited no cytotoxicity to hepatocytes and the down-regulation of pro-inflammatory cytokines in OSM-HTVi liver. Because macrophages related to wound healing and tissue repair produce the anti-inflammatory mediator, TGF-b, as well as IL-10 after the early phase of inflammation, these macrophages could contribute to pathological fibrosis when they persist in the chronically injured liver. (35) Our data showed the possibility that continuous expression of OSM is one of the environmental factors contributing to the prevalence of fibrogenic macrophages in the liver.
In addition to the environmental diversity described above, HMs are composed of at least two subpopulations, KCs and BMDMs, which are differentially regulated in liver disease. (22, 47, 48) Actually, gene expressions of some M2 markers were differentially regulated between BMDMs and KCs during OSMinduced fibrosis (Supporting Fig. S13 ). Our data suggested that HMs are responsive to OSM with regard to profibrotic activation (Figs. [4] [5] [6] and that the interaction between BMDMs and HSCs is crucial for induction of the collagen gene ( Fig. 7) . From these findings, we concluded that OSM-stimulated fibrogenic BMDMs are the key player in OSM-induced fibrosis. However, our data do not rule out the contribution of KCs to the regulation of LF because KCs also respond to OSM. Further study such as selective depletion of the KC may be necessary to understand its role in the process of LF.
Finally, the present study demonstrates that OSM is a critical factor to induce LF by suppressing fibrolysis through Timp1 expression in HSCs and promoting fibrogenesis by inducing Type1 collagen expression through the phenotypic change of macrophage ( Fig.  8 ). Considering the fact that ablation of the Osm gene ameliorates LF in the chronic hepatitis model, OSM is a promising therapeutic target. Blocking OSM signaling may be effective for the treatment of LF by decreasing collagen expression and enhancing the resolution of ECM. Further analysis is also required to clarify whether the molecular mechanisms underlying OSM-induced fibrosis are conserved in nonhepatic fibrosis. This in vivo evidence shows that OSM exerts strong fibrogenic effect by the profibrotic activation of macrophage. Further understanding of the property of macrophages activated by OSM will provide new insights into the pathogenesis of fibrotic diseases. assistance, and the members of the Miyajima and Okochi laboratory for their helpful discussion and suggestions.
